"Nov. 21, 2012 -- Women over age 40 are often urged to get yearly mammograms with the promise that early detection is their best hope for beating breast cancer.
But a new study published in The New England Journal of Medicine su"...
PERJETA is contraindicated in patients with known hypersensitivity to pertuzumab or to any of its excipients.This monograph has been modified to include the generic and brand name in many instances.
Last reviewed on RxList: 4/4/2016
Additional Perjeta Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Find support and advances in treatment.